Abreos has recently partnered with Lifeassays, a Swedish Point-of-care specialist, and formed the joint venture Aegirbio to commercialize therapeutic drug monitoring diagnostics in the autoimmune, oncology and neurology space.

​

COVID-19 update: moNATor® – Drug monitoring of Tysabri in MS

​

Ensuring continuity of care for patients living with Multiple Sclerosis (MS) during the COVID-19 pandemic is critical for patients and providers.

 

The impact of the pandemic on physical access to treatment and precautions that need to be taken by patient and provider are significant. 

 

As stated by the National Multiple Sclerosis Society, “MS itself does not increase the risk of getting COVID-19, however, certain factors associated with your MS may increase your risk for complications:

• Chronic medical conditions, such as lung disease, heart disease, diabetes or cancer

• Significantly restricted mobility, such as needing to spend most of your day seated or in bed

• Age 60 or older

• Possibly taking certain disease modifying therapies that deplete immune system cells”

 

moNATor® measures the amount of Tysabri in an MS patient’s blood. This information may help optimize treatment intervals, reducing the risk of exposure to COVID-19 and also potentially reducing the risk of progressive multifocal leukoencephalopathy (PML).

​

For more information on how to order moNATor® click here or contact us on monator@abreosbio.com